Chronic Trace, Inc.
Chronic Trace develops a research-stage platform that turns video from a commodity smartphone into objective, baseline-relative indices of brain function. A single short capture fuses involuntary signals (oculomotor and postural) with task-based measures (cognitive and reaction) into one calibrated index, the Trace Score, for decision support. The live focus today is concussion and mild TBI; the same architecture is patent-staked to extend toward stroke triage, psychiatric, and neurodegenerative monitoring. The platform is in active validation, backed by 15 U.S. patents pending, with encrypted data handling at rest and in transit. It is decision-support and research-stage, not a cleared medical device, and its outputs are intended for interpretation by qualified health professionals.
Industries
Nr. of Employees
small (1-50)
Products
Research-stage Software-as-a-Medical-Device that captures physiological and cognitive signals using short video from commodity devices, outputting multiple calibrated indices for clinical decision support.
Research-stage Software-as-a-Medical-Device that captures physiological and cognitive signals using short video from commodity devices, outputting multiple calibrated indices for clinical decision support.
Expertise Areas
- Neuro-assessment
- Digital health decision support
- Traumatic brain injury monitoring
- Manipulation-resistant digital biomarkers
Key Technologies
- Computer vision-based video assessment
- Oculomotor signal analysis
- Postural sway quantification
- Remote photoplethysmography (rPPG)
Key People
News & Updates
Discussion of recovery monitoring and the core importance of tracking return-to-baseline in brain injury assessment, describing the motivation behind Chronic Trace's methodology.
Field comparison of conventional concussion tests regarding their resistance to manipulation, contextualizing the need for involuntary biomarker-based assessment.
Explains baseline assessment limitations, issues of intentional manipulation, and the potential for objective digital biomarker approaches.
Plain account of the company's current regulatory posture, including FDA pathway, and the facts/limitations of marketing clinical claims before validation.
Monthly company updates (patents, field cohort progress, regulatory milestones, engineering, and team) for transparency and validation progress reporting.
Dispersion-based method for integrating involuntary signals into a calibrated brain health index.
Discussion of recovery monitoring and the core importance of tracking return-to-baseline in brain injury assessment, describing the motivation behind Chronic Trace's methodology.
Field comparison of conventional concussion tests regarding their resistance to manipulation, contextualizing the need for involuntary biomarker-based assessment.
Explains baseline assessment limitations, issues of intentional manipulation, and the potential for objective digital biomarker approaches.
Plain account of the company's current regulatory posture, including FDA pathway, and the facts/limitations of marketing clinical claims before validation.
Monthly company updates (patents, field cohort progress, regulatory milestones, engineering, and team) for transparency and validation progress reporting.
Dispersion-based method for integrating involuntary signals into a calibrated brain health index.